Autopsy report · NCT05034978

Novel SARS-CoV-2 Point-of-care Testing

“failure in enrolling eligible subjects during COVID-19 outbreaks”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 1 year 4 months before it stopped.
• 150 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Chinese University of Hong Kong

Sponsor type

University, hospital or other

Conditions

SARS-CoV2 Infection

Interventions

no intervention

Participants

150

Sites

1

Countries

Hong Kong

Trials that died the same way

• A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
  “COVID-19 pandemic, unable to enroll participants” (76% match in meaning)
• Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate
  “Covid 19 Pandemic - Unable to enroll patients” (73% match in meaning)
• Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
  “rate of inclusion and study affected by covid-19 epidemic” (73% match in meaning)
• Tobacco Cessation for Sexual Minorities
  “Covid-19 quarantines and closures prevented recruitment and assessment of participants.” (73% match in meaning)
• Paresthesia Free Spinal Cord Stimulation (PF-SCS)
  “Unable to recruit subjects due to Covid pandemic” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.